Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 20Lung Neoplasms 9NSCLC 3Brain Neoplasms 3Neoplasms 2Squamous Cell Carcinoma of Lung 1Non-squamous Non-small Cell Lung Cancer 1Non-small Cell Lung Cancer Metastatic 1Non-Small-Cell Lung 1Neuroma, Acoustic 1Neurofibromatosis 2 1Neoplasms, Second Primary 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Esophageal Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Bronchial Neoplasms 1Breast Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Cisplatin 7Etoposide 6Amifostine 6Radiotherapy 5Drug Therapy 5Cyclophosphamide 5apatinib 4Methotrexate 4Filgrastim 4Cytarabine 4sodium thiosulfate 3Methylprednisolone 3Carboplatin 3pegfilgrastim 2glucarpidase 2etoposide phosphate 2Voriconazole 2Vincristine 2Social Determinants of Health 2Pyridoxine 2Nivolumab 2Gemcitabine 2Doxorubicin 2Docetaxel 2Chemotherapy, Adjuvant 2Capecitabine 2trastuzumab deruxtecan 1selinexor 1sargramostim 1sacituzumab govitecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Drug-Related Side Effects and Adverse Reactions × icotinib × Clear all
NCT01963195 2017-05-08

Evaluation of the High Dose of Icotinib in Advanced Lung Cancer Patients After Failure of Target Therapy

Anhui Medical University

Phase 2 Unknown
30 enrolled

Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡